BSD Featured at Annual Meeting of the German Cancer Society

BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, announced that hyperthermia was featured at the annual meeting of the German Cancer Society (DKK [Deutscher KrebsKongress]), which was held in Berlin, Germany, February 20-25, 2012. The DKK meeting is an interdisciplinary, scientific meeting focusing on progress in cancer treatment. Focused symposia presented current scientific highlights to more than 4000 participants.

An integral part of the DKK meeting was a symposium presented by the Interdisciplinary Working Group on Hyperthermia (IAH Interdisziplinäre Arbeitsgruppe für Hyperthermie) that included 9 hyperthermia presentations. Several ongoing clinical studies were presented: a study on hyperthermia and radiation treatment of recurrent rectal cancer, sponsored by the University Medical School (UMS) of Erlangen, Germany, and a study on hyperthermia and chemotherapy treatment of primary pancreatic cancer, sponsored by the UMS of Munich, Germany.

An update of the results of the successful EORTC (European Organization for Research and Treatment of Cancer) sponsored clinical study on the use of hyperthermia and chemotherapy to treat high-risk soft tissue sarcoma was also provided to the participants. Munich UMS was the principal investigator for the sarcoma study. All of these studies utilized the BSD-2000 Hyperthermia System to deliver hyperthermia.

BSD’s line of hyperthermia products was featured at its technical exhibition booth at the Congress, which focused on state-of-the-art medical technology and drugs. "A significant number of international medical luminaries visited our booth," stated Dr. Gerhard Sennewald, CEO of Dr. Sennewald Medizintechnik GmbH, BSD’s European distributor. "There was an overwhelming interest in BSD’s top-of-the-line BSD-2000•3D/MR magnetic resonance image-guided hyperthermia system. These systems are already in clinical use at five German University Medical Schools in Berlin, Munich, Erlangen, Duesseldorf and Tuebingen."
(3.7.12)